Project Grant HT94252310824
Award Date
9/15/23
Completion Date
9/14/26
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Similar Awards
This $655,135 federal Project Grant, awarded on June 1, 2024 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a computerized screening and brief intervention for interpersonal violence among active-duty service members. The award recipient, Rhode Island Hospital, a division of Lifespan Corporation, will leverage its clinical expertise and research capabilities to conduct this 3-year project addressing this...
Health Research, Inc. Roswell Park Division received a $559,647 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research using microfluidic lung cancer models. The two-year award, made on June 1, 2023 and set to conclude on May 31, 2025, will support investigating novel drug resistance mechanisms in lung cancer through "Microfluidic Lung Cancer On A Chip" models. As a past recipient of Defense...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
Health Research, Inc. Inc Roswell Park Division Health Research Division (the Division) was awarded a $693,987 project grant from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The grant will fund cancer immunotherapy research from June 1, 2023 through May 31, 2026. Specifically, the Division will investigate strategies to counter solid tumor antigen immune escape using CAR T cell therapies. As a past recipient of Defense Health Agency...
The Department of Defense's Defense Health Agency awarded a $263,598 project grant to Brigham & Women's Hospital Inc. in Boston, MA to conduct research for the "LAM-TARGETING NANOPARTICLE-ASSISTED AND BASE EDITOR-ENABLED GENE THERAPY FOR LYMPHANGIOLEIOMYOMATOSIS" project. This 24-month grant, which runs from August 1, 2024 to July 31, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to develop novel gene therapy...
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
The Defense Health Agency awarded a $970,871 Project Grant to Brigham & Women's Hospital Inc. for the project "TARGETING METASTATIC LUNG TUMORS WITH GENE-EDITED AND ENGINEERED STEM CELLS". The grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments for lung cancer and other conditions relevant to military personnel and civilians. Brigham & Women's Hospital, a non-profit healthcare and research institution,...
The U.S. Department of Defense's Defense Health Agency awarded a $845,250 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Duke University. The grant, with a performance period from July 1, 2025 to June 30, 2028, will fund research to engineer TCR-T cells to target human endogenous retroviruses for non-small cell lung cancer immunotherapy. The goal of this advanced biomedical research is to transform healthcare for military service members, veterans, and...
The Department of Defense's Defense Health Agency awarded a $1,428,720 Project Grant to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to investigate the use of menin/KMT2A protein degradation for the treatment of myeloid neoplasms. This research, conducted under the Military Medical Research and Development (CFDA 12.420) program, aims to transform healthcare for military service members, veterans, and the broader public through advanced biomedical research. The...